2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine

Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. Currently, NVP is the most widely used anti-HIV drug in developing countries, both in combination therapy and to prevent mother-to-child transmission of HIV. Despite its efficacy against HIV, NVP produce...

Full description

Bibliographic Details
Main Authors: M. Matilde Marques, Frederick A. Beland, M. Conceição Oliveira, Benjamin Wolf, Alexandra M. M. Antunes
Format: Article
Language:English
Published: MDPI AG 2013-04-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/18/5/4955
id doaj-e433db39f6a14f459bcbf2869306662a
record_format Article
spelling doaj-e433db39f6a14f459bcbf2869306662a2020-11-25T00:17:45ZengMDPI AGMolecules1420-30492013-04-011854955497110.3390/molecules180549552'-Deoxythymidine Adducts from the Anti-HIV Drug NevirapineM. Matilde MarquesFrederick A. BelandM. Conceição OliveiraBenjamin WolfAlexandra M. M. AntunesNevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. Currently, NVP is the most widely used anti-HIV drug in developing countries, both in combination therapy and to prevent mother-to-child transmission of HIV. Despite its efficacy against HIV, NVP produces a variety of toxic responses, including hepatotoxicity and skin rash. It is also associated with increased incidences of hepatoneoplasias in rodents. In addition, epidemiological data suggest that NNRTI use is a risk factor for non-AIDS-defining cancers in HIV-positive patients. Current evidence supports the involvement of metabolic activation to reactive electrophiles in NVP toxicity. NVP metabolism includes oxidation to 12-hydroxy-NVP; subsequent Phase II sulfonation produces an electrophilic metabolite, 12-sulfoxy-NVP, capable of reacting with DNA to yield covalent adducts. Since 2’-deoxythymidine (dT) adducts from several alkylating agents are regarded as having significant mutagenic/carcinogenic potential, we investigated the formation of NVP-dT adducts under biomimetic conditions. Toward this goal, we initially prepared and characterized synthetic NVP-dT adduct standards using a palladium-mediated Buchwald-Hartwig coupling strategy. The synthetic standards enabled the identification, by LC-ESI-MS, of 12-(2'-deoxythymidin-N3-yl)-nevirapine (N3-NVP-dT) in the enzymatic hydrolysate of salmon testis DNA reacted with 12-mesyloxy-NVP, a synthetic surrogate for 12-sulfoxy-NVP. N3-NVP-dT, a potentially cytotoxic and mutagenic DNA lesion, was also the only dT-specific adduct detected upon reaction of dT with 12-mesyloxy-NVP. Our data suggest that N3-NVP-dT may be formed in vivo and play a role in the hepatotoxicity and/or putative hepatocarcinogenicity of NVP.http://www.mdpi.com/1420-3049/18/5/4955nevirapinenon-nucleoside reverse transcriptase inhibitorcarcinogenicityDNA adductspalladium catalysis
collection DOAJ
language English
format Article
sources DOAJ
author M. Matilde Marques
Frederick A. Beland
M. Conceição Oliveira
Benjamin Wolf
Alexandra M. M. Antunes
spellingShingle M. Matilde Marques
Frederick A. Beland
M. Conceição Oliveira
Benjamin Wolf
Alexandra M. M. Antunes
2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
Molecules
nevirapine
non-nucleoside reverse transcriptase inhibitor
carcinogenicity
DNA adducts
palladium catalysis
author_facet M. Matilde Marques
Frederick A. Beland
M. Conceição Oliveira
Benjamin Wolf
Alexandra M. M. Antunes
author_sort M. Matilde Marques
title 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
title_short 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
title_full 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
title_fullStr 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
title_full_unstemmed 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
title_sort 2'-deoxythymidine adducts from the anti-hiv drug nevirapine
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2013-04-01
description Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. Currently, NVP is the most widely used anti-HIV drug in developing countries, both in combination therapy and to prevent mother-to-child transmission of HIV. Despite its efficacy against HIV, NVP produces a variety of toxic responses, including hepatotoxicity and skin rash. It is also associated with increased incidences of hepatoneoplasias in rodents. In addition, epidemiological data suggest that NNRTI use is a risk factor for non-AIDS-defining cancers in HIV-positive patients. Current evidence supports the involvement of metabolic activation to reactive electrophiles in NVP toxicity. NVP metabolism includes oxidation to 12-hydroxy-NVP; subsequent Phase II sulfonation produces an electrophilic metabolite, 12-sulfoxy-NVP, capable of reacting with DNA to yield covalent adducts. Since 2’-deoxythymidine (dT) adducts from several alkylating agents are regarded as having significant mutagenic/carcinogenic potential, we investigated the formation of NVP-dT adducts under biomimetic conditions. Toward this goal, we initially prepared and characterized synthetic NVP-dT adduct standards using a palladium-mediated Buchwald-Hartwig coupling strategy. The synthetic standards enabled the identification, by LC-ESI-MS, of 12-(2'-deoxythymidin-N3-yl)-nevirapine (N3-NVP-dT) in the enzymatic hydrolysate of salmon testis DNA reacted with 12-mesyloxy-NVP, a synthetic surrogate for 12-sulfoxy-NVP. N3-NVP-dT, a potentially cytotoxic and mutagenic DNA lesion, was also the only dT-specific adduct detected upon reaction of dT with 12-mesyloxy-NVP. Our data suggest that N3-NVP-dT may be formed in vivo and play a role in the hepatotoxicity and/or putative hepatocarcinogenicity of NVP.
topic nevirapine
non-nucleoside reverse transcriptase inhibitor
carcinogenicity
DNA adducts
palladium catalysis
url http://www.mdpi.com/1420-3049/18/5/4955
work_keys_str_mv AT mmatildemarques 2039deoxythymidineadductsfromtheantihivdrugnevirapine
AT frederickabeland 2039deoxythymidineadductsfromtheantihivdrugnevirapine
AT mconceicaooliveira 2039deoxythymidineadductsfromtheantihivdrugnevirapine
AT benjaminwolf 2039deoxythymidineadductsfromtheantihivdrugnevirapine
AT alexandrammantunes 2039deoxythymidineadductsfromtheantihivdrugnevirapine
_version_ 1725378205024518144